This advisory summarizes data on the use of sublingual and transmucosal buprenorphine as part of medication-assisted treatment (MAT) for opioid use disorder.

This fact sheet developed by CDC’s National Institute for Occupational Safety and Health (NIOSH) helps employers understand the risk of opioid overdose and allows them to decide if they should establish a workplace naloxone availability and use program.